Codexis Names Robert Lawson CFO

Codexis Names Robert Lawson CFO

Redwood, CA - November 3, 2009

Codexis, Inc. today announced that Robert Lawson has been named Senior Vice President and Chief Financial Officer. Mr. Lawson will have responsibility for the company's financial, accounting and information technology operations. He will report to Alan Shaw, Ph.D., President and CEO.

Mr. Lawson joins Codexis from Intuit, where he was Vice President, Finance-Consumer Group. In that role, he provided operating financial support for the TurboTax and Quicken product lines, which generated over $1 billion in revenues in fiscal 2009. He came to Intuit in 2001 and held a series of senior financial management positions including Vice President, Investor Relations and Financial Planning and Analysis and Vice President, Finance-Small Business and Personal Finance. Previously, he served for 15 years in financial management roles at General Electric. He holds a bachelor's degree in business from Iowa State University.

"We are very pleased to welcome Bob Lawson to the Codexis senior management team," said Dr. Shaw. "His experience managing a broad range of financial operations at one of Silicon Valley's most successful high technology companies will be valuable to Codexis as our business grows to meet the global demand for clean technology."

Codexis Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes, for the energy, pharmaceutical and environmental industries. Codexis serves major worldwide markets where clean technology can make a positive economic and environmental impact. For more information, visit www.codexis.com

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.